Volume | 305 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Editas Medicine Inc | EDIT | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
7.72 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
8 | 305 | - | 6.0799 - 11.91 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
05:52:14 | formt | 163 | $ 7.86 | USD |
Editas Medicine Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
631.6M | 81.81M | - | 78.12M | -153.22M | -1.87 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Editas Medicine News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical EDIT Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 9.02 | 9.08 | 7.70 | 8.15 | 2,682,902 | -1.16 | -12.86% |
1 Month | 8.00 | 11.58 | 7.62 | 9.14 | 2,434,567 | -0.14 | -1.75% |
3 Months | 10.88 | 11.58 | 6.88 | 8.75 | 1,862,026 | -3.02 | -27.76% |
6 Months | 8.01 | 11.69 | 6.0799 | 8.77 | 1,887,271 | -0.15 | -1.87% |
1 Year | 8.37 | 11.91 | 6.0799 | 8.74 | 1,859,864 | -0.51 | -6.09% |
3 Years | 43.50 | 73.025 | 6.0799 | 19.38 | 1,752,234 | -35.64 | -81.93% |
5 Years | 24.12 | 99.95 | 6.0799 | 26.03 | 1,510,574 | -16.26 | -67.41% |
Editas Medicine Description
Editas Medicine Inc is a gene-editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company's only operating segment is developing and commercializing genome editing technology. |